Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $5.00 USD
Change Today -0.27 / -5.12%
Volume 79.5K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

fibrocell science inc (FCSC) Snapshot

Open
$5.30
Previous Close
$5.27
Day High
$5.30
Day Low
$4.98
52 Week High
06/18/15 - $6.40
52 Week Low
12/15/14 - $2.28
Market Cap
204.4M
Average Volume 10 Days
476.7K
EPS TTM
$-0.53
Shares Outstanding
40.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FIBROCELL SCIENCE INC (FCSC)

fibrocell science inc (FCSC) Related Bloomberg News

View More Bloomberg News

fibrocell science inc (FCSC) Related Businessweek News

No Related Businessweek News Found

fibrocell science inc (FCSC) Details

Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring. It is also conducting orphan gene therapy program that is in pre-clinical development stage for the treatment of recessive dystrophic epidermolysis bullosa; and gene therapy program, which is in pre-clinical development stage for linear scleroderma. The company has collaboration agreement with Intrexon Corporation for using genetically-modified autologous fibroblast cells to target proteins in patients with rare genetic skin and connective tissue disorders; and University of California, Los Angeles to focus on discoveries and technologies related to stem cells and regenerative cells in human skin. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.

50 Employees
Last Reported Date: 03/13/15
Founded in 1995

fibrocell science inc (FCSC) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $490.0K
Controller
Total Annual Compensation: $204.5K
Vice President of Scientific Affairs
Total Annual Compensation: $287.6K
Vice President of Quality
Total Annual Compensation: $148.8K
Compensation as of Fiscal Year 2014.

fibrocell science inc (FCSC) Key Developments

Fibrocell Science, Inc.(NasdaqCM:FCSC) added to Russell 2000 Index

Fibrocell Science, Inc. will be added to Russell 2000 Index

Fibrocell Science, Inc.(NasdaqCM:FCSC) added to Russell 3000 Index

Fibrocell Science, Inc. will be added to the Russell 3000 Index.

Fibrocell and Intrexon Announce Positive in Vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa at European Society of Human Genetics

Fibrocell Science, Inc. and Intrexon Corporation announced positive in vitro pre-clinical data for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The data were presented in a poster entitled "Development of a Genetically-Modified Human Dermal Fibroblast for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)" at the European Society of Human Genetics (ESHG) Conference from June 6-9, 2015 in Glasgow, Scotland, United Kingdom. RDEB is caused by a mutation of the COL7A1 gene "the gene which encodes for type VII collagen (COL7), a protein that forms anchoring fibrils to hold together the layers of skin. Without these fibrils, skin layers separate causing severe blistering, open wounds and scarring in response to any kind of friction, including normal daily activities like rubbing or scratching. In vitro product development data showed that FCX-007 (genetically-modified human dermal fibroblast, collagen VII) expresses full-length COL7 and exhibits the proper trimeric form, size, and binding functionality characteristic of anchoring fibrils, which are missing or deficient in RDEB patients. By genetically modifying autologous fibroblasts, ex vivo, to produce COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of RDEB by providing high levels of COL7 to the affected areas, avoiding systemic treatment. The data presented at ESHG show FCX-007 cells were successfully produced on cGMP-scale by expanding lentivirus-collagen type VII-transduced (LV-COL7-transduced) RDEB patient fibroblasts from a biopsy sample. The results showed: The integrated transgene copy number per cell was dose-dependent using a replication-defective, self-inactivating (SIN) lentiviral vector; The COL7 expression from the FCX-007 cells was confirmed by three different analytical methods: qRT-PCR, immunofluorescence staining and ELISA; The structure of the COL7 expressed by the FCX-007 cells was shown to be predominantly trimeric by immunoprecipitation/SDS-PAGE/Western blot analysis. Naturally-occurring COL7 primarily has this characteristic trimeric structure which is believed to be integral to the creation of anchoring fibrils of necessary strength; and The COL7 produced from the FCX-007 cells was demonstrated to be functional by binding to Laminin 332 both in an in vitro binding assay and by correction of the hypermotility phenotype of RDEB cells in an in vitro migration assay. In normal skin, COL7 anchoring fibrils bind to Laminin 332, extracellular matrix proteins, and other collagens to mediate attachment of the dermis to the epidermis. Preliminary two- and six-week toxicology results using FCX-007 cells in a human skin graft model demonstrated no findings of toxicology in RDEB human skin xenograft severe combined immunodeficiency (SCID) mice.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FCSC:US $5.00 USD -0.27

FCSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $3.68 USD +0.11
Cytori Therapeutics Inc $0.55 USD -0.003
Ocata Therapeutics Inc $5.09 USD -0.17
Organovo Holdings Inc $3.74 USD +0.03
Sangamo BioSciences Inc $9.97 USD -0.19
View Industry Companies
 

Industry Analysis

FCSC

Industry Average

Valuation FCSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.0x
Price/Book 0.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FIBROCELL SCIENCE INC, please visit www.fibrocellscience.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.